World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
28219
World Ranking
13632
National Ranking
433

Overview

Norbert Vey is affiliated with Aix-Marseille University in France and has a substantial research record primarily focused on hematology and related medical fields. Their work is positioned at the intersection of medicine, hematology, immunology, molecular biology, oncology, and genetics.

The scientist's research topics prominently include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia Research
  • Histone Deacetylase Inhibitors Research
  • Immune Cell Function and Interaction
  • Hematopoietic Stem Cell Transplantation
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Norbert Vey has contributed extensively to the literature on acute myeloid leukemia (AML) and related disorders. Some notable publications include:

  • "Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia", Blood, 2020
  • "Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation", Haematologica, 2020
  • "Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia", The Journal of Experimental Medicine, 2021
  • "Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort", Blood Advances, 2021
  • "Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study", Blood, 2021

The scientist frequently publishes in high-impact and specialized journals such as Blood, Clinical Lymphoma Myeloma & Leukemia, Leukemia, Blood Advances, and European Journal Of Haematology. Their publication volume is highest in Blood, accounting for 49 publications.

Collaborative work characterizes Norbert Vey's research approach, with frequent co-authors including:

  • Christian Récher (44 joint publications)
  • Sylvain Garciaz (42 joint publications)
  • Yosr Hicheri (29 joint publications)
  • Arnaud Pigneux (28 joint publications)
  • Pierre Péterlin (24 joint publications)

Their contributions advance understanding and treatment approaches in hematopoietic stem cell transplantation and immune cell function among other areas. Norbert Vey's research activities align closely with clinical applications and experimental medicine related to leukemia and myelodysplastic syndromes. The breadth of their work covers molecular and clinical aspects spanning immunology, genetics, and oncology.

Best Publications

  • Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia

    Véronique Gelsi-Boyer;Virginie Trouplin;José Adélaïde;Julien Bonansea

  • OUTCOME OF TREATMENT IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: ANALYSIS OF THE LALA-94 TRIAL

    Xavier Thomas;Jean Michel Boiron;Françoise Huguet;Hervé Dombret

  • Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

    R Itzykson;O Kosmider;T Cluzeau;V Mansat-De Mas

  • Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

    Raphaël Itzykson;Olivier Kosmider;Aline Renneville;Véronique Gelsi-Boyer

  • Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

    Thomas Prébet;Steven D. Gore;Benjamin Esterni;Claude Gardin

  • Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

    Raphael Itzykson;Sylvain Thépot;Bruno Quesnel;Francois Dreyfus

  • Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

    Céline Berthon;Emmanuel Raffoux;Xavier Thomas;Norbert Vey

  • Mutations of ASXL1 gene in myeloproliferative neoplasms

    N Carbuccia;A Murati;V Trouplin;M Brecqueville

  • Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

    Eric Jourdan;Nicolas Boissel;Sylvie Chevret;Eric Delabesse

  • Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy

    Ruxanda Moschoi;Ruxanda Moschoi;Véronique Imbert;Véronique Imbert;Marielle Nebout;Marielle Nebout;Johanna Chiche;Johanna Chiche

  • Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

    Sophie Park;Sophie Grabar;Charikleia Kelaidi;Odile Beyne-Rauzy

  • Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

    Sébastien Maury;Sylvie Chevret;Xavier Thomas;Dominik Heim

  • TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

    Olivier Kosmider;Véronique Gelsi-Boyer;Meyling Cheok;Sophie Grabar

  • Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience

    Lionel Adès;Lionel Adès;Agnes Guerci;Emmanuel Raffoux;Miguel Sanz

  • Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group

    Marie Balsat;Aline Renneville;Xavier Thomas;Stéphane de Botton

  • Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes

    Frederik Damm;Olivier Kosmider;Véronique Gelsi-Boyer;Véronique Gelsi-Boyer;Aline Renneville

  • A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

    Norbert Vey;Jean-Henri Bourhis;Nicolas Boissel;Dominique Bordessoule

  • Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms.

    O Kosmider;V Gelsi-Boyer;L Slama;F Dreyfus

  • TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

    Olivier Kosmider;Véronique Gelsi-Boyer;Marion Ciudad;Cindy Racoeur

  • Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial

    E. Tavernier;J. M. Boiron;F. Huguet;K. Bradstock

Frequent Co-Authors

Christian Recher
Christian Recher Federal University of Toulouse Midi-Pyrénées
Daniel Olive
Daniel Olive Aix-Marseille University
Patrice Viens
Patrice Viens Aix-Marseille University
Pierre Fenaux
Pierre Fenaux Université Paris Cité
Hervé Dombret
Hervé Dombret Université Paris Cité
Emmanuel Raffoux
Emmanuel Raffoux Hôpital Saint-Louis
Norbert Ifrah
Norbert Ifrah Grenoble Alpes University
Eric Delabesse
Eric Delabesse Cancer Research Center of Toulouse

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean following the traditional path to becoming a doctor. Today, there are a variety of medical billing and coding online programs that offer flexible entry points into healthcare administration. These courses are an excellent introduction for those interested in the crucial behind-the-scenes elements of medical practice.

Nursing remains one of the most in-demand healthcare careers. If you’re looking to minimize tuition costs, consider one of the cheapest online BSN programs to kickstart your nursing journey. Registered nurses seeking advancement may find value in researching the cheapest NP school options for nurse practitioner credentials.

For experienced nurses aiming for leadership, teaching, or research roles, affordable doctoral programs are available. Aspiring nurse leaders can explore the cheapest DNP programs online to maximize career growth while managing costs.

With a range of budget-friendly online healthcare degrees, students can find academic pathways that match both their aspirations and financial situations.

Best Scientists Citing Norbert Vey

Trending Scientists

Recently Published Articles